Current synthetic inhibitors of human neutrophil elastase in 2005

Expert Opinion on Therapeutic Patents

Volumn 15, Issue 7, 2005, Pages 759-771

  Ohbayashi, Hiroyuki ^a,b  

^a Tohno Kousei Hospital   (Japan)

^b NAGOYA UNIVERSITY   (Japan)

Author keywords

Acyl enzyme inhibitor; Elafin; Human neutrophil elastase (HNE); Protein inhibitor; Secretory leukocyte protease inhibitor (SLPI); Transition state inhibitor

Indexed keywords

1,3,4 OXADIAZOLE DERIVATIVE; 5 CYANO 4 (4 CYANOPHENYL) 6 METHYL 2 OXO 1 [3(TRIFLUOROMETHYL)PHENYL] 1,2,3,4 TETRAHYDROPYRIDINE 3 CARBOXAMIDE; [2 (3 CARBOXYMETHYL 2 OXO 1 IMIDAZOLIDINYL)ACETYL]VALYL N (3,3,3 TRIFLUORO 1 ISOPROPYL 2 OXOPROLYL)PROLINAMIDE; AE 3763; ALPHA 1 ANTITRYPSIN; DIHYDROPYRIDINE DERIVATIVE; DX 890; ELAFIN; ELASTASE INHIBITOR; ETHYL 4 (4 CYANOPHENYL) 3,6 DIMETHYL 2 OXO 1 [TRIFLUOROMETHYL)PHENYL] 1,2,3,4 DIHYDROPYRIDINE 5 CARBOXYLATE; ETHYL 6 AMINO 4 (4 CYANOPHENYL) 5 (4,4 DIMETHYL 4,5 DIHYDROOXAZOL 2 YL) 2 METHYL 1 [3(TRIFLUOROMETHYL)PHENYL] 1,4 DIHYDROPYRIDINE 3 CARBOXYLATE; FRESELESTAT; LEUKOCYTE ELASTASE; LEUKOCYTE ELASTASE INHIBITOR; MIDESTEINE; ONO 6818; PLACEBO; PROTEINASE ACTIVATED RECEPTOR 2; PYRIDONE DERIVATIVE; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; SIVELESTAT; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ACUTE LUNG INJURY; ADULT RESPIRATORY DISTRESS SYNDROME; ANTIMICROBIAL ACTIVITY; ARTIFICIAL VENTILATION; ASTHMA; ATHEROSCLEROSIS; BACTERIAL INFECTION; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CYSTIC FIBROSIS; DISEASE MODEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG RESEARCH; DRUG STRUCTURE; DRUG TARGETING; EMPHYSEMA; ENZYME SYNTHESIS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEART MUSCLE ISCHEMIA; HUMAN; INHIBITION KINETICS; LIVER DYSFUNCTION; META ANALYSIS; MOUSE; NONHUMAN; PATHOGENESIS; PERIODONTAL DISEASE; RAT; REPERFUSION INJURY; REVIEW; RHEUMATOID ARTHRITIS; SKIN DISEASE; SURVIVAL RATE; SYSTEMATIC REVIEW; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT OUTCOME;

EID: 22744446014     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.15.7.759     Document Type: Review

References (123)

1. JANOFF A, BLONDIN J: The effect of human granulocyte elastase on bacterial suspensions. Lab. Invest. (1973) 29(4):454.
2. SANDHAUS RA: Elastase may play a central role in neutrophil migration through connective tissue. In: Pulmonary emphysema and proteolysis. Taylar JC, Mittman C (Eds), New York Academic Press, USA (1987):227-233.
3. BIETH G: Elastase: catalytic and biological properties. In: Regulation of matrix accumulation. Mecham RP (Eds), Academic Press, NY, USA (1986):217-306.
4. TRAVIS J, DUBIN A, POTEMPA J, WATOREK W, KURDOWSKA A: Neutrophil proteinases. Ann. NY Acad. Sci. (1991) 624:81-86.
5. FARLEY D, FALLER B, NICK H: Therapeutic protein inhibitors of elastase. Drugs Pharm. Sci. (1997) 84:305-335.
6. BINGLE L, TETLEY TD: Secretory leukoprotease inhibitor: partnering α1-proteinase inhibitor to combat pulmonary inflammation. Thorax (1996) 51(12):1273-1274.
7. TETLEY TD: New perspectives on basic mechanisms in lung disease. 6. Proteinase imbalance: its role in lung disease. Thorax (1993) 48(5):560-565.
8. LEE WL, DOWNEY GP: Leukocyte elastase: physiological functions and role in acute lung injury. Am. J. Respir. Crit. Care Med. (2001) 164(5):896-904.
9. KAWABATA K, HAGIO T, MATSUOKA S: The role of neutrphil elastase in acute lung injury. Eur. J. Pharmacol. (2002) 451(1):1-10.
10. TAMAKUMA S, OGAWA M, AIKAWA N et al.: Relationship between neutrophil elastase and acute lung injury in humans. Pulm. Pharmacol. Ther. (2004) 17(5):271-279.
11. HIEMSTRA PS, VAN WETERING S, STOLK J: Neutrophil serine proteinases and defensins in chronic obstructive pulmonary disease: effects on pulmonary epithelium. Eur. Respir. J. (1998) 12(5):1200-1208.
12. BARNS PJ: Novel approaches and targets for treatment of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. (1999) 160(5, Pt.2):S72-S79.
13. BIRRER P: Proteases and antiproteases in cystic fibrosis: pathogenetic considerations and therapeutic strategies. Respiration. (1995) 62(Suppl. 1):25-28.
14. BALFOUR-LYNN IM: The protease-antiprotease battle in the cystic fibrosis lung. J. R. Soc. Med. (1999) 92(Suppl.37):23-30.
15. OHBAYASHI H: The pathophysiological contributions of neutrophils and neutrophil elastase to asthma. In: Focus on Asthma Research. Miroslav Tersa (Ed.), Nova Medical Books, New York, USA (2004):67-125.
16. ROYSTON D: Serine protease inhibition prevents both cellular and humoral responses to cardiopulmonary bypass. J. Cardiovasc. Pharmacol. (1996) 27(Suppl. 1):S42-S49.
17. EDMUNDS LH JR: Inflammatory response to cardiopulmonary bypass. Ann. Thorac. Surg. (1998) 66(Suppl.5):S12-S16.
18. IMAKI K, OKADA T, NAKAYAMA Y et al.: Non-peptidic inhibitors of human neutrophil elastase: the design and synthesis of sulfonanilide-containing inhibitors. Bioorg. Med. Chem. (1996) 4(12):2115-2134.
19. KAWABATA K, SUZUKI M, SUGITANI M, IMAKI K, TODA M, MIYAMOTO T: ONO-5046, a novel inhibitor of human neutrophil elastase. Biochem. Biophys. Res. Commun. (1991) 177(2):814-820.
20. YASUI S, NAGAI A, AOSHIBA K, OZZAWA Y, KAKUTA Y, KONNO K: A specific neutrophil elastase inhibitor (ONO-5046.Na) attenuates LPS-induced acute lung inflammation in the hamster. Eur. Respir. J. (1995) 8(8):1293-1299.
21. MURAKAMI K, OKAJIMA K, UCHIBA M et al.: Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats. Blood. (1996) 87(2):642-647.
22. MURAKAMI K, OKAJIMA K, UCHIBA M, OKABE H, TAKATSUKI K: Gabexate mesilate, a synthetic protease inhibitor, attenuates endotoxin-induced pulmonary vascular injury by inhibiting tumor necrosis factor production by monocytes. Crit. Care Med. (1996) 24(6):1047-1053.
23. HAGA Y, OGAWA M: Neutrophil elastase inhibitor (ONO-5046.Na) decreases production of proinflammatory cytokines by lipopolysaccharide-stimulated human monocytes. Res. Commun. Mol. Pathol. Pharmacol. (1997) 98(3):243-248.
24. ISHII K, ITO Y, KATAGIRI H, MATSUMOTO Y, KAKITA A, MAJIMA M: Neutrophil elastase inhibitor attenuates lipopolysaccharide-induced hepatic microvascular dysfunction in mice. Shock (2002) 18(2):163-168.
25. WANG HG, SHIBAMOTO T, MIYAHARA T et al.: Effect of ONO-5046, a specific neutrophil elastase inhibitor, on the phorbol myristate acetate-induced injury in isolated dog lung. Exp. Lung Res. (1999) 25(1):55-67.
26. TAOOKA Y, MAEDA A, HIYAMA K, ISHIOKA S, YAMAKIDO M: Effects of neutrophil elastase inhibitor on bleomycin-induced pulmonary fibrosis in mice. Am. J. Respir. Crit. Care Med. (1997) 156(1):260-265.
27. SAKAMAKI F, ISHIZAKA A, URANO T et al.: Effect of a specific neutrophil elastase inhibitor, ONO-5046, on endotoxin-induced acute lung injury. Am. J. Respir. Crit. Care Med. (1996) 153(1):391-397.
28. NISHINA K, MIKAWA K, TAKAO Y, MAEKAWA N, SHIGA M, OBARA H: ONO-5046, an elastase inhibitor, attenuates endotoxin-induced acute lung injury in rabbits. Anesth. Analg. (1997) 84(5):1097-1103.
29. KINOSHITA M, ONO S, MOCHIZUKI H: Neutrophils mediate acute lung injury in rabbits: role of neutrophil elastase. Eur. Surg. Res. (2000) 32(6):337-346.
30. KUBO K, KOBAYASHI T, HAYANO T et al.: Effects of ONO-5046, a specific neutrophil elastase inhibitor, on endotoxin-induced lung injury in sheep. J. Appl. Physiol. (1994) 77(3):1333-1340.
31. HAGIO T, NAKAO S, MATSUOKA H, MATSUMOTO S, KAWABATA K, OHNO H: Inhibition of neutrophil elastase activity attenuates complement-mediated lung injury in the hamster. Eur. J. Pharmacol. (2001) 426(1-2):131-138.
32. YAMAGUCHI Y, MATSUMURA F, WANG FS et al.: Neutrophil elastase enhances intercellular adhesion molecule-1 expression. Transplantation (1998) 65(12):1622-1628.
33. HAGIO T, MASTUMOTO S, NAKAO S, ABIRU T, OHNO H, KAWABATA K: Elastase inhibition reduced death associated with acid aspiration-induced lung injury in hamsters. Eur. J. Pharmacol. (2004) 488(1-3):173-180.
34. ZEIHER BG, MATSUOKA S, KAWABATA K, REPINE JE: Neutrophil elastase and acute lung injury: prospects for sivelestat and other neutrophil elastase inhibitors as therapeutics. Crit. Care Med. (2002) 30(Suppl.5):S281-S287.
35. TAMAKUWA S, SHIBA T, HIRASAWA H et al.: A Phase III clinical study of neutrophil elastase inhibitor ONO-5046 Na in SIRS patients. J. Clin. Ther. Med. (1998) 14:289-318.
36. ZEIHER BG, ARTIGAS A, VINCENT JL et al.: STRIVE STUDY GROUP: Neutrophil elastase inhibition in acute lung injury: results of the STRIVE study. Crit. Care Med. (2004) 32(8):1695-1702.
37. KADOI Y, HINOHARA H, KUNIMOTO F et al.: Pilot study of the effects of ONO-5046 in patients with acute respiratory distress syndrome. Anesth. Analg. (2004) 99(3):872-877.
38. FUJIMOTO K, KUBO K, SHINOZAKI S et al.: Neutrophil elastase inhibitor reduces asthmatic responses in allergic sheep. Respir. Physiol. (1995) 100(1):91-100.
39. TAKEYAMA K, TAMAOKI J, KONNO K, TAKIZAWA T: Effect of a neutrophil elastase inhibitor on NAP-1/ IL-8-induced stimulation of goblet cell secretion in guinea pig airways. Eur. Respir. J. (1994) 7(suppl.18):76S.
40. YOSHITAKE K, ISOHAMA Y, KAI H, TAKAHAMA K, MIYATA T: Substance P stimulates the loss of cell-associated high molecular weight glycoconjugates from cultured hamster tracheal epithelial cells through polymorphonuclear leucocytes activation. Biochem. Mol. Biol. Int. (1995) 36(5):1009-1116.
41. TAKAYAMA M, ISHIBASHI M, ISHII H, KURAKI T, NISHIDA T, YOSHIDA M: Effects of neutrophil elastase inhibitor (ONO-5046) on lung injury after intestinal ischemia-reperfusion. J. Appl. Physiol. (2001) 91(4):1800-1807.
42. ISHIKAWA N, ODA M, KAWAGUCHI M, TSUNEZUKA Y, WATANABE G: The effects of a specific neutrophil elastase inhibitor (ONO-5046) in pulmonary ischemia-reperfusion injury. Transpl. Int. (2003) 16(5):341-346.
43. DOI K, HORIUCHI T, UCHINAMI M, TABO T et al.: Neutrophil elastase inhibitor reduces hepatic metastases induced by ischaemia-reperfusion in rats. Eur. J. Surg. (2002) 168(8-9):507-510.
44. PRADELLA L: ONO-5046 Ono Pharmaceutical. Curr. Opin. Investig. Drugs. (1999) 1(5):485-501.
45. RIZZI M, CASALE E, CODA A et al.: Serine proteinase inhibition by cyclic thiolic compound YS3025: a crystallographic study. Biochem Int. (1992) 28(3):385-392.
46. CARUGO KD, RIZZI M, FASANO M et al.: Inhibition of serine proteinases belonging to the chymotrypsin superfamily by the cyclic thiolic compound YS3025: a comparative crystallographic study. Biochem. Biophys. Res. Commun. (1993) 193(1):32-39.
47. LUISETTI M, PICCIONI PD, DONNINI M et al.: Studies of MR889, a new synthetic proteinase inhibitor. Biochem. Biophys. Res. Commun. (1989) 165(2):568-573.
48. BAICI A, PELLOSO R, HORLER D: The kinetic mechanism of inhibition of human leukocyte elastase by MR889, a new cyclic thiolic compound. Biochem Pharrmacol. (1990) 39(5):919-924.
49. LUISETTI M, STURANI C, SELLA D et al.: MR889, a neutrophil elastase inhibitor, in patients with chronic obstructive pulmonary disease: a double-blind, randomized, placebo-controlled clinical trial. Eur. Resp. J. (1996) 9(7):1482-1486.
50. OHMOTO K, YAMAMOTO T, OKUMA M et al.: Development of orally active nonpeptide inhibitors of human neutrophil elastase. J. Med. Chem. (2001) 44:1268-1285.
51. OHMOTO K, OKUMURA M, YAMAMOTO T et al.: Design and synthesis of new orally active inhibitors of human neutrophil elastase. Bioorg. Med. Chem. (2001) 9(5):1307-1323.
52. OHMOTO K, YAMAMOTO T, HORIUCHI T et al.: Design and synthesis of new orally active non-peptide inhibitors of human neutrophil elastase. J. Med. Chem. (2000) 43(26): 4927-4929.
53. KURAKI T, ISHIBASHI M, TAKAYAMA M, SHIRAISHI M, YOSHIDA M: A novel oral neutrophil elastase inhibitor (ONO-6818) inhibits human neutrophil elastase-induced emphysema in rats. Am. J. Respir. Crit. Care Med. (2002) 166(4):496-500.
54. SEKIOKA T, HIROTA Y, NAKANO S et al.: Pharmacological profile of a novel orally active neutrophil elastase inhibitor, ONO-6818. Am. J. Crit. Care Med. (2001) 163:A597.
55. YOSHIMURA Y, HIRAMATSU Y, SATO Y et al.: ONO-6818, a novel, potent neutrophil elastase inhibitor, reduces inflammatory mediators during simulated extracorporeal circulation. Ann. Thorac. Surg. (2003) 76(4):1234-1239.
56. HIROTA Y, SUZUKI M, YAMAGUCHI K, FUJITA T, KATSUBE N: Effects of the neutrophil elastase inhibitor (ONO-6818) on acetic acid induced colitis in Syrian hamsters. J. Vet. Med. Sci. (2004) 66(10):1223-1228.
57. TRIFILIEFF A: ONO-6818 Cortech/Ono. Curr. Opin. Invest. Drugs (2002) 3(8):1161-1164.
58. KUBO T, OKAZAKI H, KUROMIYA A et al.: AE-3763, a novel inhibitor of neutrophil elastase (1): biochemical and pharmacological properties of AE-3763. Jpn. J. Pharmacol. (2001) 85(Suppl.1):P558.
59. KUROMIYA A, OKAZAKI H, KUBO T et al.: AE-3763, a novel inhibitor of neutrophil elastase (2): effects of AE-3763 on acute organ failure models. Jpn. J. Pharmacol. (2001) 85 (Suppl.1):P559.
60. DELACOURT C, HERIGAULT S, DELCLAUX C et al.: Protein against acute lung injury by intravenous or intratracheal pretreatment with EPI-HNE-4, a new potent neutrophil elastase inhibitor. Am. J. Respir. Cell Mol. Biol. (2002) 26:290-297.
61. DYAX CORP.: Press release (16 April 1997).
62. DELACOURT C, HERIGAULT S, DELCLAUX C et al.: Projection against acute lung injury by intravenous or intratracheal pretreatment with EPI-HNE-4, a new potent neutrophil elastase inhibitor. Am. J. Respir. Crit. Care Med. (2001) 163(Suppl.5): A490.
63. GRIMBERT D, VECELLIO L, DELEPINE P et al.: Characteristics of EPI-HNE4 aerosol: a new elastase inhibitor for treatment of cystic fibrosis. J. Aerosol Med. (2003) 16(2):121-129.
64. DUBRAY C, SAUDUBRAY F, CLAVIEN H et al.: Phase I studies with a new human neutrophil elastase inhibitor, EPI-HNE-4, administered by inhalation in healthy volunteers. Am. J. Respir. Crit. Care Med. (2001) 163(Suppl.5):A564.
65. SAUDUBRAY F, LABBE A, WALLAERT B et al.: Phase IIa clinical study of a new human neutrophil elastase inhibitor (HNE), EPI-HNE4 (DX-890), with repeated administration by inhalation in adult cystic fibrosis patients. 26th Eur. Cyst. Fibros. Conference (2003) Abst. 85.
66. BRADBURY J: Neutrophil elastase inhibitors for cystic fibrosis. Drug Discov. Today (2001) 6(9):441-442.
67. DYAX CORP.: Press release (24 February 2004).
68. DYAX CORP.: Press release (27 April 2004).
69. HONORE S, ATTALAH HL, AZOULAY E et al.: Beneficial effect on an inhibitor of leukocyte elastase (EPI-HNE-4) in presence of repeated lung injuries. Shock (2004) 22(2):131-136.
70. CARRELL RW, JEPPSSON JO, LAURELL CB et al.: Structure and variation of human α1-antitrypsin. Nature (1982) 298(5872):329-334.
71. HUBER R, CARRELL RW: Implications of the three-dimensional structure of α-1H-antitrypsin for structure and function of serpins. Biochemistry (1989) 28(23):8951-8966.
72. RENNARD SI, GHAFOURI M, THOMPSON AB et al.: Fractional processing of sequential bronchoalveolar lavage to separate bronchial and alveolar samples. Am. Rev. Respir. Dis. (1990) 141(1):208-217.
73. STOCKLEY RA, SHAW J, AFFORD SC, MORRISON HM, BUMETT D: Effect of α1-proteinase inhibitor on neutrophil chemotaxis. Am. J. Respir. Cell Mol. Biol. (1990) 2(2):163-170.
74. BUCURENCI N, BLAKE DR, CHIDWICK K, WINYARD PG: Inhibition of neutrophil superoxide production by human plasma α1-antitrypsin. FEBS Lett. (1992) 300(1):21-24.
75. WENCKER M, FUHRMANN B, BANIK N, KONIETZKO N: Longitudinal follow-up of patients withα1-protease inhibitor deficiency before and during therapy with IV with α1-protease inhibitor. Chest (2001) 19(3):737-744.
76. SANDHAUS R, STOCKS J, STOLLER J, GELMONT D, SUNDIN D, BRANTLY M: Phase I safety investigation of an aerosolized, recombinant α1-antitrypsin in subjects with α1-antitripsin deficiency. Eur. Resp. J. (2004) 24(Suppl.48):Abst. 1509.
77. DHAMI R, GILKS B, XIE C, ZAY K, WRUGHT JL, CHURG A: Acute cigarette smoke-induced connective tissue breakdown is mediated by neutrophils and prevented by α1-antitrypsin. Am. J. Respir. Cell Mol. Biol. (2000) 22(2):244-252.
78. AYAD MS, KNIGHT KR, BURDON JG, BRENTON S: Secretory leukocyte proteinase inhibitor, α1-antitrypsin deficiency and emphysema: preliminary study, speculation and an hypothesis. Respirology (2003) 8(2):175-180.
79. CHUNG A, WANG RD, XIE C, WRIGHT L: α1-Antitrypsin ameliorates cigarette smoke-induced emphysema in the mouse. Am. J. Res. Crit. Care Med. (2003) 168(2):199-207.
80. PEMBERTON PA, CANTWELL JS, WILK BJ et al.: Inhaled recombinant α1-antitrypsin ameliorates cigarette-induced damage in the smoking mouse model. Eur. Respir. J. (2004) 24(Suppl.48):1661
81. TOPPING JR, VANDEN BON EJ, TENNANT RC et al.: Effect of recombinant α1 antitrypsin (rAAT) and TAPI on neutrophil elastase (NE) and matrix metalloproteinase-9 (MMP-9) activity in induced sputum (IS) from healthy smokers and patients with chronic obstractive pulmonary disease (COPD). Eur. Respir. J. (2003) 22(Suppl.45):159.
82. GRATTON D, CANTWELL J, PEMBERTON P, BARR P, BARABE J, SUNDIN D: A study of the safety and tolerability of recombinant human α1-antitrypsin (rAAT) gel in subjects with atopic dermatitis. J. Eur. Acad. Dermatol. Venereol. (2004) 18(Suppl.2): FC07.15.
83. PROMETIC LIFE SCIENCE: Press release: (7 October 2004).
84. MOLHUIZEN HO, SCHALKWIJK J: Structural, biochemical, and cell biological aspects of the serine proteinase inhibitor SKALP/elafin/ESI. Biol. Chem. Hoppe-Seyler. (1995) 376(1):1-7.
85. SALLENAVE JM, RYLE AP: Purification and investigation of elastase-specific inhibitor, a low molecular weight proteinase inhibitor from sputum. Am. Rev. Respir. Dis. (1990) 141:A357.
86. WIEDOW O, SCHRODER JM, GREGORY H, YOUNG JA, CHRISTOPHERS E: Elafin: an elastase-specific inhibitor of human skin. Purification, characterization, and complete amino acid sequence. J. Biol. Chem. (1990) 265(25):14791-14795.
87. SALLENAVE JM, SILVA A: Characterization and gene sequence of the precursor of elafin, an elastase-specific inhibitor in bronchial secretions. Am. J. Respir. Cell Mol. Biol. (1993) 8(4):439-445.
88. NARA K, ITO S, ITO T et al.: Elastase inhibitor elafin is a new type of proteinase inhibitor which has a transglutaminase-mediated anchoring sequence termed 'cementoin'. J. Biochem. (1994) 115(3):441-448.
89. TREMBLAY GM, SALLENAVE JM, ISRAEL-ASSAYAG E, CORMIER Y, GAULDIE J: Elafin/elastase-specific inhibitor in bronchoalveolar lavage of normal subjects and farmer's lung. Am. J. Respir. Crit. Care Med. (1996) 154(4, Pt. 1):1092-1098.
90. SALLENAVE JM, SHULMANN J, CROSSLEY J, JORDANA M, GAULDIE J: Regulation of secretory leukocyte proteinase inhibitor (SLPI) and elastase-specific inhibitor (ESI/elafin) in human airway epithelial cells by cytokines and neutrophilic enzymes. Am. J. Respir. Cell Mol. Biol. (1994) 11(6):733-741.
91. SALLENAVE JM: The role of secretory leukocyte proteinase inhibitor and elafin (elastase-specific inhibitor/skin-derived antileukoprotease) as alarm antiproteinases in inflammatory lung disease. Respir. Res. (2000) 1(2):87-92.
92. TANAKA N, FUJIOKA A, TAJIMA S, ISHIBASHI A, HIROSE S: Elafin is induced in epidermis in skin disorders with dermal neutrophilic infiltration: IL-1β and tumour necrosis factor-α stimulate its secretion in vitro. Br. J. Dermatol. (2000) 143(4):728-732.
93. SUZUKI Y, FURUKAWA M, ABE J, KASHIWAGI M, HIROSE S: Localization of porcine trappin-2 (SKALP/elafin) in trachea and large intestine by in situ hybridization and immunohistochemistry. Histochem. Cell Biol. (2000) 114(1):15-20.
94. SIMPSON AJ, MAXWELL AI, GOVAN JR, HASLETT C, SALLENAVE JM: Elafin (elastase-specific inhibitor) has anti-microbial activity against Gram-positive and Gram-negative respiratory pathogens. FEBS lett. (1999) 452(3):309-313.
95. MCMICHAEL J, MAXWELL A, HAYASHI K, TAYLOR K, DORIN J, SALLENAVE JM: The antimicrobial molecule elafin protects the lung against Staphylococcus aureus infection. Eur. Respir. J. (2004) 24(Suppl.48):186.
96. MEYER-HOFFERT U, WICHMANN N, SCHWICHTENBERG L, WHITE PC, WIEDO O: Supernatants of Pseudomonas aeruginosa induce the Pseudomonas-specific antibiotic elafin in human keratinocytes. Exp. Dermatol. (2003) 12(4):418-425.
97. CUNNINGHAM G, JAMES R, MCMICHAEL G, HASLETT C, SALLENNAVE JM: The antimicrobial molecule elafin up-regulates innate immune responses in mice lungs following bacterial lipopolysaccharide challenge; a transgenic approach. Clin. Invst. Med. (2004) 274(Suppl.4):M3.9.
98. VAN WETERING S, VAN DER LINDEN AC, VAN STERKENBURG MA et al.: Regulation of secretory leukocyte proteinase inhibitor (SLPI) production by human bronchial epithelial cells: increase of cell-associated SLPI by neutrophil elastase. J. Investig. Med. (2000) 48(5):359-366.
99. REID PT, MARSDEN ME, CUNNINGHAM GA, HASLETT C, SALLENAVE JM: Human neutrophil elastase regulates the expression and secretion of elafin (elastase-specific inhibitor) in Type II alveolar epithelial cells. FEBS Lett. (1999) 457(1):33-37.
100. HENRIKSEN PA, HITT M, XING Z et al.: Adenoviral gene delivery of elafin and secretory leukocyte protease inhibitor attenuates NF-κB-dependent inflammatory responses of human endothelial cells and macrophages to atherogenic stimuli. J. Immunol. (2004) 172(7):4535-4544.
101. BAROLET AW, NILI N, CHEEMA A et al.: Arterial elastase activity after balloon angioplasty and effects of elafin, an elastase inhibitor. Arterioscler. Thromb. Vasc. Biol. (2001) 21(8):1269-1274.
102. ZAIDI SH, YOU XM, CIURA S, HUSAIN M, RABINOVITCH M: Overexpression of the serine elastase inhibitor elafin protects transgenic mice from hypoxic pulmonary hypertension. Circulation (2002) 105(4):516-521.
103. ZWIERZCHONIEWASKS M, ROBBINS RC, RABINOVITCH M, FEDOSEYEVA EV: Overexpression of elafin, a serine elastase-specific inhibitor, prevents acute cardiac allograft rejection. Am. J. Trans. (2004) 4(Suppl.8):868.
104. TOMEE JF, KOETER GH, HIEMSTRA PS, KAUFFMAN HF: Secretory leukoprotease inhibitor: a native antimicrobial protein presenting a new therapeutic option? Thorax (1998) 53(2):114-116.
105. DOUMAS S, KOLOLOTRONIS A, STEFANOPOULOS P: Anti-inflammatory and antimicrobial roles of secretory leukocyte protease inhibitor. Infect. Immun. (2005) 73(3):1271-1274.
106. SALLENAVE JM, SI-TA HAR M, COX G, CHIGNARD M, GAULDIE J: Secretory leukocyte proteinase inhibitor is a major leukocyte elastase inhibitor in human neutrophils. J. Leukoc. Biol. (1997) 61(6):695-702.
107. VAN WETERING S, VAN DER LINDEN AC, VAN STERKENBYRG MA, RABE KF, SCHALKWIJK J, HIEMSTRA PS: Regulation of secretory leukocyte proteinase inhibitor (SLPI) production by human bronchial epithelial cells: increase of cell-associated SLPI by neutrophil elastase. J. Investig. Med. (2000) 48(5):359-366.
108. SAITOH H, MASUDA T, SHIMURA S, FUSHIMI T, SHIRATO K: Secretion and gene expression of secretory leukocyte protease inhibitor by human airway submucosal glands. Am. J. Physiol. Lung Cell Mol. Physiol. (2001) 280(1):L79-87.
109. BINGLE L, TETLEY TD: Secretory leukoprotease inhibitor: partnering α1-proteinase inhibitor to combat pulmonary inflammation. Thorax (1996) 51(12):1273-1274.
110. WRIGHT CD, HAVILL AM, MIDDLETON SC et al.: Secretory leukocyte protease inhibitor prevents allergen-induced pulmonary responses in animal models of asthma. J. Pharmacol. Exp. Ther. (1999) 289(2):1007-1014.
111. SUZUKI T, WANG W, LIN JT, SHIRATO K, MITSUHASHI H, INOUE H: Aerosolized human neutrophil elastase induces airway constriction and hyperresponsiveness with protection by intravenous pretreatment with half-length secretory leukoprotease inhibitor. Am. J. Respir. Crit. Care Med. (1996) 153(4, Pt. 1):1405-1411.
112. Genomics-based Drug Data Rep. Regen. Ther. (2002) 2(6):345.
113. UEHARA A, MURAMOTO K, TAKADA H, SUGAWARA S: Neutrophil serine proteinases activate human nonepithelial cells to produce inflammatory cytokines through protease-activated receptor 2. J. Immunol. (2003) 170(11):5690-5696.
114. COTTRELL GS, COELHO AM, BUNNETT NW: Protease-activated receptors: the role of cell-surface proteolysis in signalling. Essays Biochem. (2002) 38:169-183.
115. COUGHLIN SR, CAMERER E: Participation in inflammation. J. Clin. Investig. (2003) 111:25-27.
116. D'ANDREA MR, DERIAN CK, LETURCQ D et al.: Characterization of protease-activated receptor-2 immunoreactivity in normal human tissues. J. Histochem. Cytochem. (1998) 46(2):157-164.
117. COELHO AM, OSSOVSKAYA V, BUNNETT NW: Proteinase-activated receptor-2: physiological and pathophysiological roles. Curr. Med. Chem. Cardiovasc. Hematol. Agents (2003) 1(1):61-72.
118. KNIGHT DA, LIM S, SCAFFIDI AK et al.: Protease-activated receptors in human airways: upregulation of PAR-2 in respiratory epithelium from patients with asthma. J. Allergy Clin. Immunol. (2001) 108(5):797-803.
119. BOLTON SJ, MCNULTY CA, THOMAS RJ, HEWITT CR, WARDLAW AJ: Expression of and functional responses to protease-activated receptors on human eosinophils. J. Leukoc. Biol. (2003) 74(1):60-68.
120. SCHMIDLIN F, AMADESI S, DABBAGH K et al.: Protease-activated receptor 2 mediates eosinophil infiltration and hyperreactivity in allergic inflammation of the airway. J. Immunol. (2002) 169(9):5315-5321.
121. LINDER JR, KAHN ML, COUGHLIN SR et al.: Delayed onset of inflammation in protease-activated receptor-2-deficient mice. J. Immunol. (2000) 165(11):6504-6510.
122. KAWAGOE J, TAKIZAWA T, MATSUMOTO J et al.: Effect of protease-activated receptor-2 deficiency on allergic dermatitis in the mouse ear. Jpn. J. Pharmacol. (2000) 88(1):77-84.
123. OHBAYASHI H: Current synthetic inhibitors of human neutrophil elastase. Expert Opin. Ther. Patents (2002) 12(1):65-84.